{"nctId":"NCT04523831","briefTitle":"Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection","startDateStruct":{"date":"2020-06-01","type":"ACTUAL"},"conditions":["Covid19"],"count":400,"armGroups":[{"label":"Ivermectin and Doxycycline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ivermectin and Doxycycline","Drug: Standard of care"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Standard of care"]}],"interventions":[{"name":"Ivermectin and Doxycycline","otherNames":["Imac and Doxibac"]},{"name":"Standard of care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* COVID-19 infection, confirmed by polymerase chain reaction (PCR) test within 3 days from enrollment\n* Only mild and moderate COVID-19 infected cases\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Unable to take oral medication\n* Pregnant or breast feeding lady\n* Patients with severe COVID symptoms or admission in ICU/HDU\n* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) more than 5 upper limit of normal (ULN)\n* On non-invasive positive pressure ventilation or mechanical ventilation at time of study entry\n* Known hypersensitivity to Doxycycline or ivermectin or its components.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Early Clinical Improvement","description":"Number of patients have clinical improvement as described by WHO and Bangladesh local guideline with 7 days..\n\n1. Body temperature remains normal for at least 3 days (ear temperature is lower than 37.5 Â°C).\n2. Respiratory symptoms are significantly improved.\n3. Lung imaging shows obvious improvement in lesions.\n4. There is no co-morbidities or complications which require hospitalization.\n5. SpO2, \\>93% without assisted oxygen inhalation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Late Clinical Recovery","description":"Number of the patients required more than 12 days for clinical improvement as defined above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Having Clinical Deterioration.","description":"Number of patients deteriorating to next level of severity, like moderate, severe and death. That is from mild illness at presentation with subsequent follow up developed moderate, severe illness or death. Like wise from moderate illness at presentation developed severe illness or death.\n\nMild illness: These patients usually present with symptoms of an upper respiratory tract viral infection, including mild fever, cough (dry), sore throat, nasal congestion, malaise, headache, muscle pain, or malaise. Signs and symptoms of a more serious disease, such as dyspnea, are not present Moderate illness: Respiratory symptoms such as cough and shortness of breath (or tachypnea in children) are present without signs of severe pneumonia.\n\nSevere illness:severe dyspnea, respiratory distress, tachypnea (\\> 30 breaths/min), and hypoxia (SpO2 \\< 90% on room air).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Remain Persistently Positive for RT-PCR of Covid-19","description":"Number of Patients remain positive for RT-PCR of Covid-19 at day 14 after the day of initial positivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":183},"commonTop":["Non ulcer Dyspepsia"]}}}